The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients
Open accessAbstract
Cabergoline is a new long-acting dopamine agonist that is very effective and well tolerated in patients with pathological hyperprolactinemia. The aim of this study was to examine, in a very large number of hyperprolactinemic patients, the ability to normalize PRL levels with cabergoline, to determine the effective dose and tolerance, and to assess the effect on clinical symptoms, tumor shrinkage, and visual field abnormalities. We also evaluated the effects of cabergoline in a large subgroup of patients with bromocriptine intolerance or -resistance. We retrospectively reviewed the files of 455 patients (102 males and 353 females) with pathological hyperprolactinemia treated with cabergoline in 9 Belgian centers. Among these patients, 41% had a microadenoma; 42%, a macroadenoma; 16%, idiopathic hyperprolactinemia; and 1%, an empty sella. The median pretreatment serum PRL level was 124 μg/L (range, 16–26,250 μg/L). A subgroup of 292 patients had previously been treated with bromocriptine, of which 140 showed bromocriptine intolerance and 58 showed bromocriptine resistance. Treatment with cabergoline normalized serum PRL levels in 86% of all patients: in 92% of 244 patients with idiopathic hyperprolactinemia or a microprolactinoma and in 77% of 181 macroadenomas. Pretreatment visual field abnormalities normalized in 70% of patients, and tumor shrinkage was seen in 67% of cases. Side effects were noted in 13% of patients, but only 3.9% discontinued therapy because of side effects. The median dose of cabergoline at the start of therapy was 1.0 mg/week but could be reduced to 0.5 mg/week once control was achieved. Patients with a macroprolactinoma needed a higher median cabergoline dose, compared with those with idiopathic hyperprolactinemia or a microprolactinoma: 1.0 mg/week vs. 0.5 mg/week, although a large overlap existed between these groups. Twenty-seven women treated with cabergoline became pregnant, and 25 delivered a healthy child. One patient had an intended abortion and another a miscarriage. In the patients with bromocriptine intolerance, normalization of PRL was reached in 84% of cases, whereas in the bromocriptine-resistant patients, PRL could be normalized in 70%. We confirmed, in a large-scale retrospective study, the high efficacy and tolerability of cabergoline in the treatment of pathological hyperprolactinemia, leaving few patients with unacceptable side effects or inadequate clinical response. Patients with idiopathic hyperprolactinemia or a microprolactinoma, on average, needed only half the dose of cabergoline as those with macroprolactinomas and have a higher chance of obtaining PRL normalization. Cabergoline also normalized PRL in the majority of patients with known bromocriptine intolerance or -resistance. Once PRL secretion was adequately controlled, the dose of cabergoline could often be significantly decreased, which further reduced costs of therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea
Webster, J., Piscitelli, G., Polli, A., Ferrari, C. I., Ismail, I., & Scanlon, M. F. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311403 · Cited by 699
Dopamine Agonists and Pituitary Tumor Shrinkage
BEVAN, J. S., WEBSTER, J., Burke, C. W., & Scanlon, M. F. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-2-220 · Cited by 469
Sex-Related Difference in the Growth of Prolactinomas: A Clinical and Proliferation Marker Study1
Delgrange, E., Trouillas, J., Maiter, D., Donckier, J., & Tourniaire, J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4088 · Cited by 277
Self-citationProlactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment
Colao, A. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.3.876 · Cited by 276
Resistance to Bromocriptine in Prolactinomas
PELLEGRINI, I., RASOLONJANAHARY, R., GUNZ, G., BERTRAND, P., DELIVET, S., JEDYNAK, C. P., KORDON, C., PEILLON, F., JAQUET, P., & ENJALBERT, A. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-3-500 · Cited by 267
Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline
Biller, B. M. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.6.2338 · Cited by 216
Sex-Related Difference in the Growth of Prolactinomas: A Clinical and Proliferation Marker Study
Delgrange, E. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.7.2102 · Cited by 181
Pregnancy outcome after treatment with the ergot derivative, cabergoline
Robert, E., Musatti, L., Piscitelli, G., & Ferrari, C. I. (1996) · Reproductive Toxicology · doi:10.1016/0890-6238(96)00063-9 · Cited by 178
Long-Term and Low-Dose Treatment with Cabergoline Induces Macroprolactinoma Shrinkage
Colao, A., Di Sarno, A., Landi, M. L., Cirillo, S., Sarnacchiaro, F., Facciolli, G., Pivonello, R., Cataldi, M., Merola, B., Annunziato, L., et al. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.11.4368 · Cited by 163
Rains, C. P., Bryson, H. M., & Fitton, A. (1995) · Drugs · doi:10.2165/00003495-199549020-00009 · Cited by 155
Cited by
Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline
Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1692 · Cited by 1,844
PREDICT: a method for inferring novel drug indications with application to personalized medicine
Gottlieb, A., Stein, G. Y., Ruppin, E., & Sharan, R. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.26 · Cited by 881
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
Casanueva, F. F., Molitch, M. E., Schlechte, J. A., Abs, R., Bonert, V., Bronstein, M. D., Brue, T., Cappabianca, P., Colao, A., Fahlbusch, R., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02562.x · Cited by 829
Self-citationAdvances in the Treatment of Prolactinomas
Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A. (2006) · Endocrine Reviews · doi:10.1210/er.2005-9998 · Cited by 824
Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia
Colao, A., Di Sarno, A., Cappabianca, P., Di Somma, C., Pivonello, R., & Lombardi, G. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022657 · Cited by 336
Colao, A., Sarno, A., Cappabianca, P., Briganti, F., Pivonello, R., Somma, C., Faggiano, A., Biondi, B., & Lombardi, G. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480325 · Cited by 267
Colao, A., Vitale, G., Cappabianca, P., Briganti, F., Ciccarelli, A., De Rosa, M., Zarrilli, S., & Lombardi, G. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030979 · Cited by 256
Hyperprolactinemia and Prolactinomas
Mancini, T., Casanueva, F. F., & Giustina, A. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2007.10.013 · Cited by 256
Specificity of the neuroendocrine response to orgasm during sexual arousal in men
Kruger, T., Haake, P., Chereath, D., Knapp, W., Janssen, O., Exton, M., Schedlowski, M., & Hartmann, U. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1770057 · Cited by 175
De Rosa, M., Ciccarelli, A., Zarrilli, S., Guerra, E., Gaccione, M., Di Sarno, A., Lombardi, G., & Colao, A. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02461.x · Cited by 76
Prolactin in Human Reproduction
Molitch, M. E. (2009) · Yen & Jaffe's Reproductive Endocrinology · doi:10.1016/b978-1-4160-4907-4.00003-6 · Cited by 31
Metadata
- Authors
- Verhelst, J., Abs, R., Maiter, D., van den Bruel, A., Vandeweghe, M., Velkeniers, B., Mockel, J., Lamberigts, G., Petrossians, P., Coremans, P., Mahler, C., Stevenaert, A., Verlooy, J., Raftopoulos, C., & Beckers, A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1999-07-01
- Volume
- 84
- Issue
- 7
- Pages
- 2518-2522
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2161513867
- Cited by
- 449
- References
- 19
- FWCI
- 9.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.